<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irene de Boer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gisela M Terwindt, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3424670010"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is an autosomal dominant inherited angiopathy caused by mutations in the three-prime repair exonuclease 1 (<em>TREX1</em>) gene [<a href="#rid1">1,2</a>]. RVCL-S is an underrecognized disorder. The main causes of morbidity and mortality are vascular retinopathy, focal neurologic complaints including ischemic events and cognitive decline, and kidney failure [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H243310094"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Other terms used for RVCL-S in early reports include the following [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebroretinal vasculopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary vascular retinopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary endotheliopathy, retinopathy, nephropathy, and stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary systemic angiopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Retinal vasculopathy with cerebral leukodystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Retinal vasculopathy with cerebral leukoencephalopathy</p><p></p><p class="headingAnchor" id="H204691897"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>RVCL-S is caused by carboxyl terminal (C-terminal) truncating mutations in the three-prime repair exonuclease 1 (<em>TREX1</em>) gene [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H1471096808"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>RVCL-S is an autosomal dominant condition caused by heterozygous frameshift or nonsense pathogenic variants in the carboxyl terminal (C-terminal) of the <em>TREX1</em> gene [<a href="#rid1">1,2</a>]. Fewer than 15 pathogenic variants of <em>TREX1</em> are known to cause RVCL-S [<a href="#rid1">1,3-7</a>]. The most frequently diagnosed pathogenic variant is a frameshift mutation (<em>V235Gfs*6</em>).</p><p>Although penetrance seems to be 100 percent, the clinical course of RVCL-S is highly variable between and within families [<a href="#rid1">1</a>]. While it seems probable that index patients are more severely affected than other relatives, this is not always the case, and the issue is complicated by misdiagnosis of family members [<a href="#rid1">1,8</a>]. More research is needed to further assess family members with a relatively late disease onset and a relatively slow progression.</p><p><em>TREX1</em> has two major domains. The N-terminus, containing three exonuclease sequence motifs, is responsible for exonuclease activity and maintains innate immune tolerance to self-DNA [<a href="#rid9">9-11</a>]. The C-terminal domain is required for its localization to and its interaction with the endoplasmic reticulum [<a href="#rid2">2,9,12-14</a>].</p><p>Pathogenic variants leading to RVCL-S result in a truncated TREX1 protein. The exonuclease function of TREX1 is not affected while the subcellular localization is shifted [<a href="#rid2">2,13,14</a>], which alters its interaction with the endoplasmic reticulum.</p><p>RVCL-S is not the only disease associated with pathogenic variants in <em>TREX1</em>. Variants affecting the exonuclease function of <em>TREX1</em> are associated with three autoimmune diseases:</p><p class="bulletIndent1"><span class="glyph">●</span>Aicardi-Goutières syndrome, an early-onset encephalopathy caused by pathogenic variants in several genes, including <em>TREX1</em> [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial chilblain lupus, a rare form of chilblain lupus erythematosus that is caused by heterozygous pathogenic variants in the <em>TREX1</em> or <em>SAMHD1</em> genes. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)", section on 'Chilblain lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic predisposition to systemic lupus erythematosus. (See  <a class="medical medical_review" href="/z/d/html/4669.html" rel="external">"Epidemiology and pathogenesis of systemic lupus erythematosus", section on 'Genetic factors'</a>.)</p><p></p><p>Moreover, a synonymous variant in <em>TREX1</em> (ie, no change in amino acid) was associated with an increased risk of systemic sclerosis in one report [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1253863773"><span class="h2">Vascular changes</span><span class="headingEndMark"> — </span>The underlying lesion of RVCL-S is a nonatherosclerotic, amyloid-negative angiopathy involving small arteries and capillaries, primarily in the retina and brain, but also in other organs [<a href="#rid1">1,18</a>].</p><p>Morphologic studies have demonstrated thicker multilaminated basement membranes and fibrous thickening of small vessel walls in patients with RVCL-S [<a href="#rid1">1</a>]. While <em>TREX1</em> transcripts have been identified at the RNA level in all tissues examined, more research is needed into the endogenous expression of the protein and the mutated protein [<a href="#rid19">19</a>]. <em>TREX1</em> was found to be expressed in a subset of microglia in the normal human brain, often in close proximity to the microvasculature. Interestingly, in ischemic lesions, the amount of <em>TREX1</em>-positive microglia was increased [<a href="#rid20">20,21</a>]. This indicates a possible role for <em>TREX1</em> and microglia in vessel homeostasis and response to ischemic injury. There is also an increased expression of <em>TREX1</em> in the undamaged white matter of patients with RVCL-S, suggestive of a widespread ongoing injury that cannot be detected histologically [<a href="#rid20">20,21</a>]. Moreover, <em>TREX1</em> was found to be expressed in endothelial cells in the brain of a RVCL-S patient indicating a possible direct effect on endothelium function [<a href="#rid21">21</a>].</p><p>Besides the morphologic alterations, other indications of vessel pathology in RVCL-S are also present. These include impairment of endothelial function [<a href="#rid22">22</a>] and elevated markers of chronic endothelial activation (von Willebrand factor and angiopoietin-2) [<a href="#rid23">23</a>]. Furthermore, impaired cerebrovascular reactivity, a marker for cerebrovascular health, is found in patients with RVCL-S [<a href="#rid24">24</a>].</p><p>Animal studies have found that, compared with wild-type littermates, RVCL-S transgenic knock-in mice have increased mortality, evidence of abnormal vascular function, and increased infarct volume with experimental stroke [<a href="#rid25">25</a>].</p><p>Autoinflammation could also contribute towards the observed phenotype. One study found that both erythrocyte-sedimentation rate (ESR) and fibrinogen levels were elevated in patients with RVCL-S [<a href="#rid18">18</a>]. It has been hypothesized that immune activation in RVCL-S is due to immunogenic free glycans release demonstrated in lymphoblasts of patients with RVCL-S [<a href="#rid13">13</a>]. Furthermore, in a conditional knock-in mice model of RVCL-S (carrying the <em>V235Gfs*6 </em>pathogenic variant), a distinct autoantibody profile was found compared with wild-type mice [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2870479782"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Most autopsy studies have been carried out in patients with advanced disease, and several (nonspecific) findings have been reported. Histopathologic examination of the retina has demonstrated scattered microinfarctions, hemorrhages, and neovascularization [<a href="#rid1">1</a>]. Additionally, retinal artery walls show thickening and the ganglion cell and inner nuclear layer of the retina can be focally disrupted [<a href="#rid1">1</a>].</p><p>Macroscopic evaluation of the brain demonstrates involvement of the periventricular white matter, particularly in the frontoparietal regions. In few cases, the brainstem and cerebellum were also involved. Microscopic examination of the brain can also show ischemic areas, thickening of vessel walls, and substantial myelin loss [<a href="#rid1">1,21</a>]. In some patients there is a modest chronic inflammatory cell infiltrate near ischemic lesions [<a href="#rid1">1</a>]. Frequently, focal calcifications and reactive astrocytosis are demonstrated [<a href="#rid1">1,21</a>]. Less often, vascular telangiectasia are found [<a href="#rid1">1</a>].</p><p>Examination of the liver demonstrates nodular regenerative hyperplasia and steatosis, periportal inflammation, and bridging. In the kidney, arterio- or arteriolonephrosclerosis and focal or diffuse glomerulosclerosis have been found [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3917183073"><span class="h2">Genotype-phenotype correlations</span><span class="headingEndMark"> — </span>No clear genotype-phenotype associations have been identified. Patients with RVCL-S demonstrate a surprisingly similar phenotype. An association between a higher age of onset and the <em>V235fs </em>mutation has been described [<a href="#rid1">1,27</a>]; however, as few patients have been described, this observation requires further confirmation.</p><p class="headingAnchor" id="H1327089122"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>RVCL-S is rare. Worldwide, fewer than 35 families with confirmed RVCL-S had been identified as of 2022 [<a href="#rid1">1,3-8,14,21,28-33</a>]. However, this number is likely to be an underestimate, given the finding of three unrelated families with RVCL-S in one small country (the Netherlands) alone [<a href="#rid1">1</a>]. Moreover, RVCL-S is often confused with other disorders (see <a class="local">'Differential diagnosis'</a> below). With more awareness and new genetic screening techniques, such as whole exome sequencing, new cases and more families will be identified.</p><p class="headingAnchor" id="H3898614429"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H4193702805"><span class="h2">Major features</span><span class="headingEndMark"> — </span>The clinical presentation of RVCL-S differs between and within families. The primary manifestations are:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular retinopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Features of focal and/or global brain dysfunction with the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ischemic stroke and transient ischemic attack (TIA)</p><p class="bulletIndent2"><span class="glyph">•</span>Non-ischemic events leading to acute or subacute focal and global deficits</p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive decline</p><p class="bulletIndent2"><span class="glyph">•</span>Migraine</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Psychiatric disturbances</p><p></p><p>Additional features often include renal dysfunction, liver dysfunction, anemia, hypertension, Raynaud phenomenon, and subclinical hypothyroidism [<a href="#rid1">1,18</a>]. Less common manifestations include avascular necrosis of the femoral head, (hypertensive) cardiomyopathy, and cutaneous abnormalities (macular rash and punctate skin lesions) [<a href="#rid3">3,6,8,14,34,35</a>].</p><p class="headingAnchor" id="H746772503"><span class="h3">Age of onset</span><span class="headingEndMark"> — </span>The onset of symptoms with RVCL-S occurs in adulthood, typically between 30 and 50 years of age [<a href="#rid1">1</a>]. Medical assistance is also frequently sought earlier because of a positive family history [<a href="#rid1">1</a>]. Presenting symptoms are most often visual complaints or neurologic dysfunction. It is observed that the age at onset of migraine in patients with RVCL-S may be high (40 years), whereas onset of disease normally is in adolescence (&lt;25 years), which suggests that migraine may occur secondary to the vasculopathy [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1433551958"><span class="h3">Vascular retinopathy</span><span class="headingEndMark"> — </span>Symptomatic retinopathy appears to develop in all patients with RVCL-S [<a href="#rid1">1,3-5,14,30,36-39</a>]. Decreased visual acuity and/or visual field defects due to vascular retinopathy are the most common presenting symptoms of RVCL-S [<a href="#rid1">1</a>]. Vascular retinopathy is characterized in the early stages by telangiectasia, micro-aneurysms, and cotton wool spots. Later, perifoveal capillary obliterations and neovascularizations occur [<a href="#rid1">1,38</a>]. Secondary glaucoma and macula edema can develop as complications of the retinopathy. (See <a class="local">'Ophthalmologic examination'</a> below.)</p><p class="headingAnchor" id="H336431355"><span class="h3">Neurologic manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic episodes</strong> – Ischemic stroke and TIAs are manifestations of RVCL-S. Ischemic episodes present as a classic lacunar syndromes (eg, pure motor stroke, ataxic-hemiparesis, dysarthria-clumsy hand syndrome, pure sensory stroke, sensorimotor stroke), but other lacunar syndromes (brainstem or hemispheric) are also observed [<a href="#rid1">1,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/1136.html" rel="external">"Lacunar infarcts"</a>.)</p><p></p><p class="bulletIndent1">Note that it may be difficult to distinguish ischemic events from nonischemic causes of acute focal dysfunction in RVCL-S.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute or acute focal and global brain dysfunction</strong> – Neurologic symptoms are frequent in RVCL-S. Focal neurologic symptoms and cognitive impairment are described in 68 and 56 percent of symptomatic patients, respectively [<a href="#rid1">1</a>]. At time of death, 97 percent of mutation carriers had focal brain features and 75 percent had cognitive impairment [<a href="#rid1">1</a>]. A wide range of focal neurologic symptoms are found [<a href="#rid1">1,3-5,7,14,30,36,37</a>].</p><p></p><p class="bulletIndent1">Focal neurologic symptoms (eg, hemiparesis, aphasia, facial weakness, hemianopsia) can be associated with intracerebral mass lesions  (<a class="graphic graphic_diagnosticimage graphicRef127199" href="/z/d/graphic/127199.html" rel="external">image 1</a>), called pseudotumors [<a href="#rid1">1,3,5-7,14,35-37</a>]. (See <a class="local">'Neuroimaging'</a> below.)</p><p></p><p class="bulletIndent1">The global brain dysfunction seen in RVCL-S can manifest as many different complaints, most frequently bradyphrenia, apathy, irritability, and complaints of memory and judgement [<a href="#rid1">1,30,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive decline</strong> – Cognitive deficits are one of the most frequent features of RVCL-S, observed in about 56 percent of symptomatic patients [<a href="#rid1">1</a>]. Cognitive decline seems to be slowly progressive, with additional stepwise deterioration superimposed, as may be seen in other hereditary small vessel disorders. Neuropsychologic testing usually shows deficits in multiple cognitive domains including working memory, executive function, and cognitive processing speed [<a href="#rid1">1,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migraine</strong> – Migraine (with and without aura) occurs in up to 42 percent of RVCL-S cases [<a href="#rid1">1</a>]. Migraine onset in patients with RVCL-S often occurs in adulthood (eg, age 40 years), whereas migraine onset in the general population typically occurs in childhood or adolescence, which suggests that migraine may occur secondary to the vasculopathy [<a href="#rid18">18</a>]. Unlike other small-vessel conditions associated with migraine (ie, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]), RVCL-S has not been associated with atypical aura symptoms such as prolonged auras (&gt;60 minutes), motor auras, or auras with acute onset [<a href="#rid1">1,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epilepsy</strong> – In a large cross-sectional study 17 percent of patients with RVCL-S suffered from seizures [<a href="#rid1">1,14,37</a>].</p><p></p><p class="headingAnchor" id="H576562416"><span class="h3">Psychiatric disturbances</span><span class="headingEndMark"> — </span>Mood disorders occur in 42 percent of patients. Many patients develop adjustment disorder or moderate depression, but major depression, psychosis, anxiety, and other psychiatric complaints have all been reported [<a href="#rid1">1,14,37</a>]. Apathy, defined as a primary loss of motivation, has been reported in clinical practice. Although apathy frequently occurs with depression, apathy may develop in the absence of depression [<a href="#rid1">1,14,37</a>].</p><p class="headingAnchor" id="H4216599925"><span class="h3">Systemic manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal disease</strong> – Renal involvement occurs in approximately 30 to 50 percent of the patients [<a href="#rid1">1,18</a>]. Most frequently kidney involvement has a mild phenotype, however, occasionally fatal stage 4 kidney disease occurs [<a href="#rid1">1,3,4,14,30,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase are the most frequent manifestations of liver disease in RVCL-S [<a href="#rid1">1,30,35,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional symptoms</strong> – RVCL-S patients appear to suffer from hypertension [<a href="#rid1">1,3,4,18,39</a>]. Additionally, mild to moderate anemia occurs, which may be explained, at least partially, by the microscopic gastrointestinal bleeding that occurs in RVCL-S [<a href="#rid1">1,4,18</a>]. Raynaud phenomenon, usually mild, is present without causing ischemic injury [<a href="#rid1">1,18,39</a>]. One study demonstrated subclinical hypothyroidism as part of the phenotype [<a href="#rid18">18</a>]. Some evidence suggests that the phenotype should be extended to include avascular necrosis of the femoral head, hypertension, cardiomyopathy, and skin lesions [<a href="#rid3">3,6,8,14,34,35</a>].</p><p></p><p>There are no reports that RVCL-S is associated with complications during pregnancy.</p><p class="headingAnchor" id="H2143382937"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H1178465506"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of RVCL-S should be suspected when adult patients of middle age (eg, 30 to 50 years) present with vascular retinopathy (eg, with retinal cotton-wool spots, perifoveal telangiectasias and capillary obliteration, peripheral focal capillary occlusion, and microvascular abnormalities), and/or focal or global neurologic deficits, with characteristic "pseudotumors" and/or small T2 hyperintense lesions on brain magnetic resonance imaging (MRI) with or without gadolinium enhancement (see <a class="local">'Neuroimaging'</a> below), particularly in the setting of a positive family history of retinopathy or neurologic disease. (See <a class="local">'Ophthalmologic examination'</a> below.)</p><p>Note that a negative family history does not exclude RVCL-S, since de novo pathogenic variants of three-prime repair exonuclease 1 (<em>TREX1</em>) are reported [<a href="#rid14">14,32</a>]. Furthermore, family members with RVCL-S may be misdiagnosed with other conditions (eg, neurodegenerative disorder, brain tumor, multiple sclerosis, hypertensive, diabetic retinopathy). (See <a class="local">'Potential misdiagnosis'</a> below.)</p><p class="headingAnchor" id="H3710502627"><span class="h2">Confirming the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of RVCL-S is confirmed with the identification of a heterozygous pathogenic variant in <em>TREX1</em> by molecular genetic testing. (See <a class="local">'Molecular genetic testing'</a> below.)</p><p>Pathologic confirmation (eg, by brain biopsy) is not required.</p><p class="headingAnchor" id="H3103750339"><span class="h2">Investigations</span><span class="headingEndMark"> — </span>Patients suspected of having RVCL-S should be evaluated with the following investigations:</p><p class="bulletIndent1"><span class="glyph">●</span>Molecular genetic testing, if the clinical features, neuroimaging, and/or laboratory studies are consistent with a possible or probable diagnosis of RVCL-S</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain MRI with and without gadolinium contrast, if not already performed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmologic examination (including determining intraocular pressure, <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography, and optical coherence tomography), if not already done</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of urinary protein excretion (ie, urine protein and urine creatinine via a 24-hour urine collection or spot sample)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver enzymes, including serum aminotransferases, alkaline phosphatase, and gamma-glutamyltransferase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count including hemoglobin, hematocrit, red blood cell (RBC) count, RBC indices, white blood cell (WBC) count, platelets, WBC differential, and reticulocytes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examination of the peripheral blood smear</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function studies, beginning with serum thyroid stimulating hormone (TSH), followed by serum free thyroxine (T4) if the TSH level is elevated</p><p></p><p class="headingAnchor" id="H2220620958"><span class="h3">Ophthalmologic examination</span><span class="headingEndMark"> — </span>On ophthalmologic examination, patients with RVCL-S may have retinal cotton-wool spots, perifoveal telangiectasias and capillary obliteration, peripheral focal capillary occlusion, and microvascular abnormalities, predominantly affecting the posterior pole  (<a class="graphic graphic_diagnosticimage graphicRef135064" href="/z/d/graphic/135064.html" rel="external">image 2</a>) [<a href="#rid42">42,43</a>]. Optical coherence tomography imaging often demonstrates peripapillary retinal nerve fiber layer thinning and a reduced total macular volume. Notably, in patients with a normal funduscopic examination, retinal thinning can sometimes already be detected [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H875436847"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>Several different types of lesions have been described on MRI, which are all located in the white matter, sparing the cortex [<a href="#rid1">1,24,45</a>].</p><p>The most striking lesions are pseudotumors (also termed tumefactive brain lesions) that occur in up to 75 percent of symptomatic patients with RVCL-S [<a href="#rid1">1,27</a>]. Pseudotumors are mass lesions that are surrounded by extensive edema, which may lead to displacement of adjacent structures and sulci effacement  (<a class="graphic graphic_diagnosticimage graphicRef127199" href="/z/d/graphic/127199.html" rel="external">image 1</a>). Pseudotumors are hyperintense on T2-weighted images, hypointense on T1-weighted images, and show ring enhancement with gadolinium contrast [<a href="#rid1">1,3,5-8,14,35-37</a>]. These lesions may grow in size, remain stable, or shrink over time [<a href="#rid24">24</a>].</p><p>Besides these tumefactive brain lesions, hyperintense T2-weighted punctate lesions with nodular or rim enhancement on T1-weighted sequences after gadolinium contrast frequently occur in periventricular and deep white matter, and in the basal ganglia  (<a class="graphic graphic_diagnosticimage graphicRef127198" href="/z/d/graphic/127198.html" rel="external">image 3</a>) [<a href="#rid1">1,4,24,45</a>]. They are sometimes associated with diffusion restriction. Rim-enhancing lesions with prolonged diffusion restriction and long-lasting contrast enhancement are characteristic imaging findings in RVCL-S  (<a class="graphic graphic_diagnosticimage graphicRef127200" href="/z/d/graphic/127200.html" rel="external">image 4</a>) [<a href="#rid24">24,45</a>].</p><p>Patients with RVCL-S can also have one or more punctate, contrast-enhancing lesions in the cerebellum, often bilateral. Cerebellar lesions appear to develop with more advanced disease and often increase in number over the years. Progression in size with rim enhancement is rare [<a href="#rid24">24</a>].</p><p>Susceptibility artefact is frequently seen in brain lesions on MRI [<a href="#rid4">4,24</a>]. As calcifications often occur in RVCL-S (best seen on computed tomography [CT] images) [<a href="#rid1">1,27</a>], not all susceptibility artefacts should be interpreted as microbleeds.</p><p>Small T2 hyperintense lesions, with minimal or no enhancement on T1 after gadolinium contrast, may be associated with diffusion restriction on MRI or calcifications on CT [<a href="#rid1">1</a>]. These lesions are present in the periventricular and deep white matter and, although nonspecific as solitary finding, occur more frequently than expected after accounting for the age of the patient [<a href="#rid1">1,4,7,35</a>].</p><p class="headingAnchor" id="H1887294065"><span class="h3">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory examinations demonstrate the systemic nature of the disease. The abnormalities include manifestations of [<a href="#rid1">1,3,4,14,18,30,35-37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney disease, demonstrated by increased serum creatinine and/or proteinuria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease, demonstrated by elevated liver enzymes, most frequently alkaline phosphatase and gamma-glutamyltransferase; in case of severe liver enzyme abnormalities, an ultrasound of the liver can be obtained and repeated to monitor for liver cirrhosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic anemia, most frequently normocytic and normochromic; a gastroscopy and/or colonoscopy can be performed to screen for gastrointestinal bleeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical hypothyroidism as shown by elevated TSH and normal free T4</p><p></p><p>All abnormalities can range from mild to severe and might require treatment or further monitoring.</p><p class="headingAnchor" id="H1008325864"><span class="h3">Molecular genetic testing</span><span class="headingEndMark"> — </span>The approach to molecular genetic testing can involve single gene testing with sequence analysis of <em>TREX1</em>, or a multigene panel that evaluates <em>TREX1</em> and other genes of interest, such as those causing adult-onset leukoencephalopathies and cerebral angiopathies [<a href="#rid46">46</a>]. Multigene panels may vary by laboratory in the included genes and the method of testing.</p><p class="headingAnchor" id="H57211195"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>While there are no universally accepted diagnostic criteria for RVCL-S, the following criteria have been proposed [<a href="#rid18">18,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic confirmation:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of a C-terminal truncating pathogenic variant in <em>TREX1</em> confirms the diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major features:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vascular retinopathy </p><p class="bulletIndent2"><span class="glyph">•</span>Features of focal and/or global brain dysfunction associated on MRI with one or both of the following:</p><p class="bulletIndent3"><span class="glyph">-</span>Punctate T2 hyperintense white matter lesions with nodular enhancement</p><p class="bulletIndent3"><span class="glyph">-</span>Larger T2 hyperintense white matter mass lesions with rim-enhancement, mass effect, and surrounding edema</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of autosomal dominant inheritance with middle-age onset of disease manifestations (de novo mutations are possible)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive features:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On CT, focal white matter calcifications and/or on MRI, non-enhancing punctate T2 hyperintense white matter lesions at an age that nonspecific, age-related white matter hyperintensities are infrequent</p><p class="bulletIndent2"><span class="glyph">•</span>Microvascular liver disease (nodular regenerative hyperplasia)</p><p class="bulletIndent2"><span class="glyph">•</span>Microvascular kidney disease (arterio- or arteriolonephrosclerosis, glomerulosclerosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia consistent with blood loss and/or chronic disease</p><p class="bulletIndent2"><span class="glyph">•</span>Microscopic gastrointestinal bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Subclinical hypothyroidism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possibly associated features:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Raynaud phenomenon (typically mild)</p><p class="bulletIndent2"><span class="glyph">•</span>Migraine with or without aura</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension</p><p></p><p>In order to firmly establish the diagnosis, documentation of a typical <em>TREX1</em> pathogenic variant by genetic analysis is required.</p><p class="headingAnchor" id="H3763241282"><span class="h2">Potential misdiagnosis</span><span class="headingEndMark"> — </span>RVCL-S is frequently misdiagnosed as brain tumor, multiple sclerosis, vasculitis, neurodegenerative disorder, diabetic retinopathy, or other conditions [<a href="#rid1">1</a>]. Furthermore, unnecessary biopsies (eg, brain, kidney, and liver) have been performed as part of the evaluation.</p><p class="headingAnchor" id="H3478778867"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Due to the systemic nature of RVCL-S, the differential diagnosis is very broad. As such, the combination of symptoms and a family history consistent with an autosomal dominant inheritance pattern are important for the diagnosis. MRI of the brain can be helpful in the differential diagnosis as rim-enhancing lesions with prolonged diffusion restriction and long-lasting contrast enhancement are characteristic imaging findings in RVCL-S [<a href="#rid45">45</a>].</p><p>A comprehensive differential diagnosis, attained by using the primary characteristics of RVCL-S, consists of a number of acquired and hereditary conditions discussed in the sections that follow.</p><p class="headingAnchor" id="H718784897"><span class="h2">Acquired disorders</span><span class="headingEndMark"> — </span>The differential diagnosis of RVCL-S includes the following acquired disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Sporadic small vessel disease (SVD) with or without hypertension as the main risk factor (see  <a class="medical medical_review" href="/z/d/html/1136.html" rel="external">"Lacunar infarcts"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple sclerosis (see  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system vasculitis (see  <a class="medical medical_review" href="/z/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracranial neoplasm (see  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multi-infarct dementia (see  <a class="medical medical_review" href="/z/d/html/5085.html" rel="external">"Etiology, clinical manifestations, and diagnosis of vascular dementia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus (see  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis (see  <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Susac syndrome, a rare disorder associated with the clinical triad of visual loss caused by branch retinal artery occlusions, sensorineural hearing loss, and subacute encephalopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (SLE; most frequently in SLE no autosomal inheritance pattern or genetic cause is found; however, in rare cases, monogenic SLE has been described (both autosomal dominant and recessive [<a href="#rid47">47,48</a>]) (see  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a>)</p><p></p><p>Unlike RVCL-S, acquired disorders do not have a family history of autosomal dominant inheritance. However, RVCL-S could have been misdiagnosed or a de novo mutation could have occurred, so the absence of a family history alone does not exclude RVCL-S. (See <a class="local">'Potential misdiagnosis'</a> above.)</p><p>The major difference between multiple sclerosis, intracranial neoplasms, and multi-infarct dementia is that RVCL-S involves multiple organs besides the brain. Central nervous system vasculitis usually only involves the brain and is often associated with hemorrhages, which are rare in RVCL-S. Likewise, the stenosis and dilations of the vasculature seen in a vasculitis are absent in RVCL-S.</p><p>While diabetes mellitus, sarcoidosis, and SLE are all systemic diseases cerebral and liver involvement are usually absent. Characteristic granulomas are seen in sarcoidosis that are absent in RVCL-S, and SLE differs from RVCL-S in the prominent cutaneous involvement, the elevated antibody profiles, and the presence of oral and/or nasal ulcers, alopecia, and arthritis. In Susac syndrome, hearing loss is much more frequently reported and the pattern of white matter lesions is different from RVCL-S.</p><p class="headingAnchor" id="H3154713721"><span class="h2">Inherited disorders</span><span class="headingEndMark"> — </span>The differential diagnosis of RVCL-S includes the following inherited disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), due to pathogenic variants in the <em>NOTCH3</em> gene (see  <a class="medical medical_review" href="/z/d/html/1091.html" rel="external">"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), which is caused by pathogenic variants in the <em>HTRA1</em> gene [<a href="#rid49">49,50</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), which is due to pathogenic variants in the <em>CTSA</em> gene [<a href="#rid51">51,52</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>COL4A1</em>-<em> </em>and <em>COL4A2</em>-related disorders [<a href="#rid53">53</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fabry disease, which is caused by pathogenic variants in the <em>GLA </em>gene (see  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">"Fabry disease: Neurologic manifestations"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurofibromatosis type 1, which is due to pathogenic variants in the <em>NF1 </em>gene (see  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberous sclerosis complex, which is caused by pathogenic variants in the <em>TSC1</em> and <em>TSC2 </em>genes (see  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>)</p><p></p><p>The mode of inheritance differs between RVCL-S (autosomal dominant) and CARASIL or CARASAL (both autosomal recessive) and Fabry disease (X-linked recessive) [<a href="#rid49">49,51,54</a>]. Additionally, spasticity of lower extremities, spondylosis deformans, and alopecia are important features in CARASIL [<a href="#rid49">49</a>]. In CARASAL, cerebral hemorrhages occur; however, the entire phenotypic spectrum of CARASAL may not be fully described given the small number of reported cases [<a href="#rid51">51</a>]. The earlier onset of symptoms and the presence of angiokeratomas, hyperhidrosis, and corneal opacity that characterize Fabry disease can help to distinguish it from RVCL-S [<a href="#rid54">54</a>].</p><p>Like RVCL-S, CADASIL, neurofibromatosis type 1, <em>COL4A1</em>- and<em> COL4A2</em>-related disorders, and tuberous sclerosis complex have an autosomal dominant inheritance pattern [<a href="#rid55">55-58</a>]. However, CADASIL does not involve other organs and there is a distinct white matter lesion pattern consisting of white matter T2 hyperintensities on MRI in the anterior temporal lobe and external capsule [<a href="#rid55">55</a>]. Neurofibromatosis type 1 differs due to its distinct skin lesions, the presence of distinct osseous lesions, and a pattern of bright spots on T2-weighted MRI of the brain, which are seen commonly in children with neurofibromatosis type 1 but may disappear in adulthood; they occur most often in the basal ganglia, cerebellum, brainstem, and subcortical white matter [<a href="#rid56">56</a>]. Age of onset in <em>COL4A1</em>-<em> </em>and<em> COL4A2</em>-related disorders is highly variable but frequently occurs earlier than in RVCL-S. Moreover, infantile hemiparesis, hemorrhagic strokes, porencephaly (fluid-filled cavities in the brain detected by neuroimaging), intellectual disability, hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) syndrome and cerebral large vessel involvement (ie, aneurysms) occur. Moreover, isolated retinal artery tortuosity and congenital cataract can occur due to <em>COL4A1</em> mutations [<a href="#rid57">57</a>]. Tuberous sclerosis complex is often diagnosed in children and causes distinct skin and lung lesions as well as hamartomas, which are all absent in RVCL-S [<a href="#rid58">58</a>].</p><p>MELAS is a mitochondrial disease primarily affecting the central nervous system and muscles. The disease has a broad phenotype including lactic acidemia, myopathy, hearing impairment, diabetes, and short stature. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MELAS'</a>.)</p><p>In addition to differences in clinical features, molecular genetic testing with a gene panel to detect pathogenic variants causing cerebral angiopathies and adult-onset leukoencephalopathies can often be useful for distinguishing these inherited disorders.</p><p class="headingAnchor" id="H2773887147"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no specific disease-modifying treatment for RVCL-S. One clinical trial investigated aclarubicin, hypothesized to correct glycan release demonstrated in lymphoblasts of patients with RVCL-S, but the trial was discontinued after only four participants were included [<a href="#rid59">59</a>]. A pilot trial studying the effectiveness of <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">crizanlizumab</a> is in progress [<a href="#rid60">60</a>].</p><p>Given the rarity of RVCL-S, only limited data are available regarding the management of the major manifestations of the disease.</p><p class="headingAnchor" id="H1209837859"><span class="h2">Genetic counseling</span><span class="headingEndMark"> — </span>Consultation with a clinical geneticist who is knowledgeable about RVCL-S is recommended when a patient is first diagnosed.</p><p>In addition, asymptomatic at-risk family members should be offered genetic counseling. Predictive testing is possible once a three-prime repair exonuclease 1 (<em>TREX1</em>) pathogenic variant has been identified in an affected family member. Potential consequences of such a test should be discussed (eg, socioeconomic effects, potential health benefits). RVCL-S differs from many hereditary neurologic diseases because early diagnosis with genetic screening can identify individuals who may benefit from prompt initiation of treatment of complications and preventive measures. Evaluation of signs of retinopathy is especially important as treatment before the onset of visual complaints may prevent early blindness.</p><p class="headingAnchor" id="H1953056829"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>To establish the extent of the disease, the following evaluations are recommended at time of diagnosis to determine the individual needs of the patient if they have not already been completed. (See <a class="local">'Investigations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Eyes – Ophthalmologic evaluation, <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography, and optical coherence tomography for signs of retinopathy, macular edema, and glaucoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrum – Brain MRI (if not already done) and assessment for signs of focal brain dysfunction, cognitive impairment, symptoms of migraine, seizures, and/or psychiatric symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney – Assessment of renal function (serum creatinine, urinalysis, and protein excretion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver – Assessment of liver enzymes (serum aminotransferases, alkaline phosphatase, and gamma glutamyl transpeptidase) and albumin. If severe liver enzyme changes are detected, lactate dehydrogenase and bilirubin can be determined and coagulations test can be performed. Liver ultrasound can be used to monitor for cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular – Assessment of blood pressure for hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic – Complete blood count and hemoglobin to look for anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid – Thyroid stimulating hormone [TSH] and free thyroxine [T4]) to look for subclinical hypothyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other – Assessment for symptoms of Raynaud phenomenon.</p><p></p><p>These evaluations should be repeated at least annually in patients diagnosed with RVCL-S to detect treatable complications and symptoms. More frequent monitoring might be necessary if symptoms are severe. If the lesions seen on brain MRI are medium to large in size, a brain MRI should be repeated at shorter intervals. In addition, a brain MRI should be obtained if neurologic signs or symptoms occur.</p><p>Referral for specialist care is indicated for patients with evidence of significant neurologic or systemic involvement due to RVCL-S. However, these specialists should be informed about RVCL-S and its diverse manifestations in order to avoid needless diagnostics procedures (like biopsies) and to prevent undertreatment or overtreatment.</p><p class="headingAnchor" id="H3124102259"><span class="h2">Symptomatic therapy</span><span class="headingEndMark"> — </span>Most symptoms of RVCL-S should be treated with standard care, including glaucoma, hypertension, migraine, seizures, hypothyroidism, anemia, Raynaud phenomenon, and psychiatric complaints.</p><p>For renal disease, control of hypertension is especially important.</p><p>Retinopathy and macular edema can be treated with retinal laser photocoagulation and intravitreal antivascular endothelial growth factor (anti-VEGF) therapy. Elevated eye pressure should be treated with standard care.</p><p>If patients suffer from anemia, coagulation of possible gastrointestinal malformations can be tried. However, in some patients, numerous small malformations occur, making coagulation of all these lesions impossible. If so, or if no malformations are found, standard care should be administrated. For severe anemia, intravenous iron therapy or blood transfusions may be necessary. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p>For symptomatic patients with imaging evidence of vasogenic cerebral edema, which is commonly associated with tumefactive white matter lesions, treatment with a course of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> followed by oral glucocorticoids is a reasonable but unproven intervention [<a href="#rid1">1</a>]. Although evidence of efficacy is lacking, we treat tumefactive brain lesions with intravenous methylprednisolone 1000 mg daily for three days, followed by an oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper starting at 60 mg and tapering by 5 mg every five days. Depending upon the response (assessed by evaluating neurologic deficits and neuroimaging), the taper can be reinstituted at a slower rate or at smaller decrements.</p><p>Migraine and seizures should be treated with standard care; however, CGRP antagonists are contraindicated [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H2452196818"><span class="h2">Ischemic stroke and TIA</span><span class="headingEndMark"> — </span>Transient ischemic attack and acute ischemic stroke in patients with RVCL-S are managed following the general principles of stroke medicine. (See  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p>However, intravenous thrombolytic therapy is not recommended for patients with RVCL=S who have acute ischemic stroke. There is no proof that intravenous thrombolytic therapy is effective in this setting, and, as RVCL-S is an angiopathy, the bleeding risk with thrombolytic therapy may be increased. In patients with multiple microbleeds, a sign of small vessel disease, intravenous thrombolytic therapy is associated with higher risks [<a href="#rid62">62,63</a>].</p><p>For secondary stroke prevention in patients with RVCL-S who have a symptomatic ischemic event confirmed by MRI, available risk reduction strategies should be employed, including antiplatelet therapy, statin treatment, and treatment for hypertension and diabetes mellitus. In addition, smoking cessation may be particularly important. Other suggested lifestyle modifications include limited alcohol consumption, weight control, regular physical activity, and a Mediterranean diet that is rich in fruits, vegetables, and low-fat dairy products. However, specific evidence that these measures are effective for reducing stroke risk in RVCL-S is lacking. (See  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a>.)</p><p class="headingAnchor" id="H110713468"><span class="h1">CLINICAL COURSE AND PROGNOSIS</span><span class="headingEndMark"> — </span>RVCL-S is a progressive disorder, but the rate of progression is variable. Visual impairment is most frequently the presenting symptom, while cognitive impairment appears to have a later onset. (See <a class="local">'Clinical features'</a> above.)</p><p>While symptoms can remain stable for long periods of time, progression can also occur precipitously. Neurologic symptoms may be mild until the age of 50 to 55 years, after which symptoms progress rapidly during the last stage of the disease. To further elucidate the clinical course further studies are required.</p><p>Life expectancy in RVCL-S is decreased, with an average age of death 53 years (standard deviation +/- 9.6, range 32 to 72) in one study [<a href="#rid1">1</a>]. The most common cause of death is infection (pneumonia or sepsis) in the setting of general debilitation.</p><p class="headingAnchor" id="H1704509033"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a rare autosomal dominantly inherited angiopathy caused by mutations in the three-prime repair exonuclease 1 (<em>TREX1</em>) gene. (See <a class="local">'Pathophysiology'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The onset of symptoms related to RVCL-S occurs most often between 30 and 50 years of age. The major clinical manifestations are retinopathy, focal neurologic symptoms including ischemic events, and cognitive impairment. Other symptoms include liver disease, kidney disease, anemia, gastrointestinal bleeding, subclinical hypothyroidism, Raynaud phenomenon, migraine with and without aura, and hypertension. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of RVCL-S is suspected when middle-aged adults present with vascular retinopathy associated with focal or global neurologic deficits, particularly in the setting of a positive family history of retinopathy or neurologic disease. The diagnosis can be confirmed by documentation of a frameshift or nonsense pathogenic variant in the C-terminus of <em>TREX1</em>. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Due to the systemic nature of RVCL-S, the differential diagnosis is very broad and includes many acquired and inherited disorders. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain MRI typically reveals several different types of lesions in the white matter in patients with RVCL-S, including pseudotumors (tumefactive lesions), punctate hyperintense T2-weighted lesions with nodular or rim-enhancement, and nonenhancing T2 hyperintense lesions more numerous than expected based upon the patient's age. Rim-enhancing lesions with prolonged diffusion restriction and long-lasting contrast enhancement are characteristic imaging findings. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no specific disease-modifying treatment for RVCL-S. Treatment is mainly symptomatic. Annual monitoring is recommended to detect treatable complications. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RVCL-S is progressive, ending in premature death. However, the clinical course is highly variable between and within families. (See <a class="local">'Clinical course and prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stam AH, Kothari PH, Shaikh A, et al. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain 2016.</a></li><li><a class="nounderline abstract_t">Richards A, van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39:1068.</a></li><li><a class="nounderline abstract_t">Vodopivec I, Oakley DH, Perugino CA, et al. A 44-year-old man with eye, kidney, and brain dysfunction. Ann Neurol 2016; 79:507.</a></li><li><a class="nounderline abstract_t">Schuh E, Ertl-Wagner B, Lohse P, et al. Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL. Neurol Neuroimmunol Neuroinflamm 2015; 2:e55.</a></li><li><a class="nounderline abstract_t">Dhamija R, Schiff D, Lopes MB, et al. Evolution of brain lesions in a patient with TREX1 cerebroretinal vasculopathy. Neurology 2015; 85:1633.</a></li><li><a class="nounderline abstract_t">Riley CS, Roth LA, Sampson JB, et al. A 31-Year-Old Man With a Ring-Enhancing Brain Lesion. J Neuroophthalmol 2017; 37:172.</a></li><li><a class="nounderline abstract_t">Carra-Dalliere C, Ayrignac X, Prieto-Morin C, et al. TREX1 Mutation in Leukodystrophy with Calcifications and Persistent Gadolinium-Enhancement. Eur Neurol 2017; 77:113.</a></li><li><a class="nounderline abstract_t">Hardy TA, Young S, Sy JS, et al. Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation? J Neurol Neurosurg Psychiatry 2017.</a></li><li><a class="nounderline abstract_t">Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'--&gt;5' exonucleases. J Biol Chem 1999; 274:19655.</a></li><li><a class="nounderline abstract_t">Höss M, Robins P, Naven TJ, et al. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J 1999; 18:3868.</a></li><li><a class="nounderline abstract_t">Yan N. Immune Diseases Associated with TREX1 and STING Dysfunction. J Interferon Cytokine Res 2017; 37:198.</a></li><li><a class="nounderline abstract_t">Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med (Berl) 2007; 85:531.</a></li><li><a class="nounderline abstract_t">Hasan M, Fermaintt CS, Gao N, et al. Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. Immunity 2015; 43:463.</a></li><li><a class="nounderline abstract_t">DiFrancesco JC, Novara F, Zuffardi O, et al. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci 2015; 36:323.</a></li><li><a class="nounderline abstract_t">Crow YJ, Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet 2009; 18:R130.</a></li><li class="breakAll">Crow YJ. Aicardi-Goutières syndrome. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1475/ (Accessed on February 26, 2020).</li><li><a class="nounderline abstract_t">Hughes M, Little J, Herrick AL, et al. A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia. Scand J Rheumatol 2017; 46:77.</a></li><li><a class="nounderline abstract_t">Pelzer N, Hoogeveen ES, Haan J, et al. Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. J Intern Med 2019; 285:317.</a></li><li><a class="nounderline abstract_t">Mazur DJ, Perrino FW. Excision of 3' termini by the Trex1 and TREX2 3'--&gt;5' exonucleases. Characterization of the recombinant proteins. J Biol Chem 2001; 276:17022.</a></li><li><a class="nounderline abstract_t">Kothari PH, Kolar GR, Jen JC, et al. TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia. Brain Pathol 2018; 28:806.</a></li><li><a class="nounderline abstract_t">Saito R, Nozaki H, Kato T, et al. Retinal Vasculopathy With Cerebral Leukodystrophy: Clinicopathologic Features of an Autopsied Patient With a Heterozygous TREX 1 Mutation. J Neuropathol Exp Neurol 2019; 78:181.</a></li><li><a class="nounderline abstract_t">de Boer I, Stam AH, Buntinx L, et al. RVCL-S and CADASIL display distinct impaired vascular function. Neurology 2018; 91:e956.</a></li><li><a class="nounderline abstract_t">Pelzer N, Bijkerk R, Reinders MEJ, et al. Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. Stroke 2017; 48:3301.</a></li><li><a class="nounderline abstract_t">Hoogeveen ES, Pelzer N, de Boer I, et al. Neuroimaging Findings in Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations. AJNR Am J Neuroradiol 2021; 42:1604.</a></li><li><a class="nounderline abstract_t">Mulder IA, Rubio-Beltran E, Ibrahimi K, et al. Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. Stroke 2020; 51:300.</a></li><li><a class="nounderline abstract_t">Sakai T, Miyazaki T, Shin DM, et al. DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice. J Autoimmun 2017; 81:13.</a></li><li><a class="nounderline abstract_t">Raynowska J, Miskin DP, Pramanik B, et al. Retinal vasculopathy with cerebral leukoencephalopathy (RVCL): A rare mimic of tumefactive MS. Neurology 2018; 91:e1423.</a></li><li><a class="nounderline abstract_t">Gulati A, Bale AE, Dykas DJ, et al. TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD-A Novel Presentation. Am J Kidney Dis 2018; 72:895.</a></li><li><a class="nounderline abstract_t">Monroy-Jaramillo N, Cerón A, León E, et al. Phenotypic Variability in a Mexican Mestizo Family with Retinal Vasculopathy with Cerebral Leukodystrophy and TREX1 Mutation p.V235Gfs*6. Rev Invest Clin 2018; 70:68.</a></li><li><a class="nounderline abstract_t">Gruver AM, Schoenfield L, Coleman JF, et al. Novel ophthalmic pathology in an autopsy case of autosomal dominant retinal vasculopathy with cerebral leukodystrophy. J Neuroophthalmol 2011; 31:20.</a></li><li><a class="nounderline abstract_t">Yan Y, Jiang S, Wang R, et al. Serial magnetic resonance imaging changes of pseudotumor lesions in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a case report. BMC Neurol 2021; 21:219.</a></li><li><a class="nounderline abstract_t">Macaron G, Khoury J, Hajj-Ali RA, et al. Novel de novo TREX1 mutation in a patient with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations mimicking demyelinating disease. Mult Scler Relat Disord 2021; 52:103015.</a></li><li><a class="nounderline abstract_t">Wilms AE, de Boer I, Terwindt GM. Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives. Cereb Circ Cogn Behav 2022; 3:100046.</a></li><li><a class="nounderline abstract_t">Gutmann DH, Fischbeck KH, Sergott RC. Hereditary retinal vasculopathy with cerebral white matter lesions. Am J Med Genet 1989; 34:217.</a></li><li><a class="nounderline abstract_t">Winkler DT, Lyrer P, Probst A, et al. Hereditary systemic angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy, and hepatopathy. J Neurol 2008; 255:77.</a></li><li><a class="nounderline abstract_t">Cohn AC, Kotschet K, Veitch A, et al. Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome. Clin Exp Ophthalmol 2005; 33:181.</a></li><li><a class="nounderline abstract_t">Mateen FJ, Krecke K, Younge BR, et al. Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation. Neurology 2010; 75:1211.</a></li><li><a class="nounderline abstract_t">Storimans CW, Van Schooneveld MJ, Oosterhuis JA, Bos PJ. A new autosomal dominant vascular retinopathy syndrome. Eur J Ophthalmol 1991; 1:73.</a></li><li><a class="nounderline abstract_t">Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain 1998; 121 ( Pt 2):303.</a></li><li><a class="nounderline abstract_t">Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49:1322.</a></li><li><a class="nounderline abstract_t">Ford AL, Chin VW, Fellah S, et al. Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathy. Neurology 2020; 95:e1918.</a></li><li><a class="nounderline abstract_t">Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology 1988; 95:649.</a></li><li><a class="nounderline abstract_t">Qian Y, Kosmorsky G, Kaiser PK. Retinal manifestations of cerebroretinal vasculopathy. Semin Ophthalmol 2007; 22:163.</a></li><li><a class="nounderline abstract_t">de Boer I, Steenmeijer SR, Pelzer N, et al. Spectral Domain Optical Coherence Tomography in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: A Monogenic Small Vessel Disease. J Neuroophthalmol 2022; 42:e130.</a></li><li><a class="nounderline abstract_t">Hedderich DM, Lummel N, Deschauer M, et al. Magnetic Resonance Imaging Characteristics of Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations. Clin Neuroradiol 2020; 30:229.</a></li><li class="breakAll">de Boer I, Pelzer N, Terwindt G. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK546576/ (Accessed on February 26, 2020).</li><li><a class="nounderline abstract_t">Yasutomo K, Horiuchi T, Kagami S, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001; 28:313.</a></li><li><a class="nounderline abstract_t">Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol 2018; 9:2496.</a></li><li><a class="nounderline abstract_t">Ibrahimi M, Nozaki H, Lee A, et al. A CARASIL Patient from Americas with Novel Mutation and Atypical Features: Case Presentation and Literature Review. Cerebrovasc Dis 2017; 44:135.</a></li><li class="breakAll">Onodera O, Nozaki H, Fukutake T. HTRA1 disorder. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK32533/ (Accessed on February 26, 2020).</li><li><a class="nounderline abstract_t">Finsterer J, Scorza CA, Scorza FA, Wakil SM. Update on hereditary, autosomal dominant cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL). Acta Neurol Belg 2019; 119:299.</a></li><li><a class="nounderline abstract_t">Bugiani M, Kevelam SH, Bakels HS, et al. Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL). Neurology 2016; 87:1777.</a></li><li><a class="nounderline abstract_t">Zagaglia S, Selch C, Nisevic JR, et al. Neurologic phenotypes associated with COL4A1/2 mutations: Expanding the spectrum of disease. Neurology 2018; 91:e2078.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Ries M. Fabry Disease: A Disorder of Childhood Onset. Pediatr Neurol 2016; 64:10.</a></li><li><a class="nounderline abstract_t">Di Donato I, Bianchi S, De Stefano N, et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Med 2017; 15:41.</a></li><li><a class="nounderline abstract_t">Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am 2019; 103:1035.</a></li><li><a class="nounderline abstract_t">Meuwissen ME, Halley DJ, Smit LS, et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet Med 2015; 17:843.</a></li><li><a class="nounderline abstract_t">Randle SC. Tuberous Sclerosis Complex: A Review. Pediatr Ann 2017; 46:e166.</a></li><li class="breakAll">Aclarubicin for the treatment of retinal vasculopathy with cerebral leukodystrophy (RVCL). https://clinicaltrials.gov/ct2/show/NCT02723448 (Accessed on February 22, 2022).</li><li class="breakAll">Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL) https://clinicaltrials.gov/ct2/show/NCT04611880 (Accessed on February 23, 2022).</li><li><a class="nounderline abstract_t">de Boer I, MaassenVanDenBrink A, Terwindt GM. The potential danger of blocking CGRP for treating migraine in CADASIL patients. Cephalalgia 2020; 40:1676.</a></li><li><a class="nounderline abstract_t">Charidimou A, Shoamanesh A, International META-MICROBLEEDS Initiative. Clinical relevance of microbleeds in acute stroke thrombolysis: Comprehensive meta-analysis. Neurology 2016; 87:1534.</a></li><li><a class="nounderline abstract_t">Schlemm L, Endres M, Werring DJ, Nolte CH. Benefit of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With High Cerebral Microbleed Burden. Stroke 2020; 51:232.</a></li></ol></div><div id="topicVersionRevision">Topic 126686 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27604306" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660820" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691497" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A 44-year-old man with eye, kidney, and brain dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566545" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527794" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evolution of brain lesions in a patient with TREX1 cerebroretinal vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079760" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A 31-Year-Old Man With a Ring-Enhancing Brain Lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28013302" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : TREX1 Mutation in Leukodystrophy with Calcifications and Persistent Gadolinium-Enhancement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28794152" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391904" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'--&gt;5' exonucleases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393201" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475463" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immune Diseases Associated with TREX1 and STING Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440703" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320659" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213617" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808788" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808788" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574969" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30411414" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279105" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Excision of 3' termini by the Trex1 and TREX2 3'--&gt;5' exonucleases. Characterization of the recombinant proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062819" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561700" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Retinal Vasculopathy With Cerebral Leukodystrophy: Clinicopathologic Features of an Autopsied Patient With a Heterozygous TREX 1 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076273" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : RVCL-S and CADASIL display distinct impaired vascular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114091" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34167956" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuroimaging Findings in Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31805844" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325644" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194247" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Retinal vasculopathy with cerebral leukoencephalopathy (RVCL): A rare mimic of tumefactive MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941221" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD-A Novel Presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718010" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phenotypic Variability in a Mexican Mestizo Family with Retinal Vasculopathy with Cerebral Leukodystrophy and TREX1 Mutation p.V235Gfs*6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131853" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Novel ophthalmic pathology in an autopsy case of autosomal dominant retinal vasculopathy with cerebral leukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34107918" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Serial magnetic resonance imaging changes of pseudotumor lesions in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34044261" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Novel de novo TREX1 mutation in a patient with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations mimicking demyelinating disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36324396" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817001" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hereditary retinal vasculopathy with cerebral white matter lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204807" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hereditary systemic angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy, and hepatopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807828" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876473" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1821204" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A new autosomal dominant vascular retinopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9549508" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371916" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887784" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3174024" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebroretinal vasculopathy. A new hereditary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763237" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Retinal manifestations of cerebroretinal vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34334759" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Spectral Domain Optical Coherence Tomography in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: A Monogenic Small Vessel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30627749" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Magnetic Resonance Imaging Characteristics of Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30627749" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Magnetic Resonance Imaging Characteristics of Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479590" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutation of DNASE1 in people with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30459768" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Monogenic Lupus: A Developing Paradigm of Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28628911" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A CARASIL Patient from Americas with Novel Mutation and Atypical Features: Case Presentation and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28628911" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A CARASIL Patient from Americas with Novel Mutation and Atypical Features: Case Presentation and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177426" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Update on hereditary, autosomal dominant cathepsin-A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664989" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413629" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neurologic phenotypes associated with COL4A1/2 mutations: Expanding the spectrum of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27555236" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fabry Disease: A Disorder of Childhood Onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28231783" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582003" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Diagnosis and Management of Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25719457" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414398" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tuberous Sclerosis Complex: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414398" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tuberous Sclerosis Complex: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414398" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tuberous Sclerosis Complex: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660269" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The potential danger of blocking CGRP for treating migraine in CADASIL patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27629086" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical relevance of microbleeds in acute stroke thrombolysis: Comprehensive meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739772" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Benefit of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With High Cerebral Microbleed Burden.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
